BioSpace News Archive

Scientific collaborators at Stanford University will present preclinical data for novel neuro-imaging agent, 18 F-OP-801, for Alzheimer’s Disease and other neurodegenerative diseases marked by neuroinflammation

Surmodics, Inc. today announced the successful first clinical uses of of the Sublime™ Radial Access .018 RX PTA Dilatation Catheter.

The Janssen Pharmaceutical Companies today announced the initiation of its Phase 3 EVERGREEN study.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that on August 23, 2021 it entered into a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. (Pierre Fabre), a subsidiary of the Pierre Fabre group which distribute products in over 100 countries around the world.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced results from a Drug-Drug Interaction (‘DDI’) study with its lead drug candidate, CRV431.

Checkpoint Surgical announces the full commercial release of the Checkpoint Guardian Nerve Stimulator, the next generation of its classic intraoperative nerve stimulation technology.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the publication of results from a ground-breaking global genetic study in the New England Journal of Medicine, including findings of a potential treatment of structural birth defects caused by specific gene alterations.

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress.